Question special
Lead Moderator

Hi everyone! Many thanks to the authors and experts for participating in this Q&A forum. We will be discussing the articles ‘Prospective Validation of a 21-Gene Expression Assay in Breast Cancer’ & ‘Biology before Anatomy in Early Breast Cancer’.

In the authors’ conclusions, it was noted that “among patients with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer who met established guidelines for the recommendation of adjuvant chemotherapy on the basis of clinicopathologic features, those with tumors that had a favorable gene-expression profile [using this assay] had very low rates of recurrence at 5 years with endocrine therapy alone.”

To start quite open-ended, what are some initial thoughts about the results and conclusions of the study?